In my most recent Money and Markets articles, I’ve put you on the inside track about a rapidly growing, yet mostly still under-the-radar, industry. One that the world’s super-rich are quietly funding with their own money, in pursuit of potentially eye-popping investment returns.
I then told you that industry was the legal cannabis business.
What’s more, I reported that, according to reputable market research, the legal marijuana industry in the U.S. was a $3.4 billion business in 2015. In 2016, this market doubled to $7.1 billion.
Now, two major studies show that legal marijuana sales will top $40 billion in the U.S. over the next five years. That number could surge to $50 billion over the next decade … or sooner.
Marijuana is legal in more than half of the states in the U.S., for medicinal and even recreational use. With marijuana going mainstream, some of corporate America’s most-profitable and high-profile industries are recognizing the threat marijuana poses to their profits.
And they are starting to fight back in a big way …
Last week, you learned that the marijuana industry’s biggest enemy is not the Trump administration or U.S. Attorney General Jeff Sessions.
Rather, it’s the Big Pharma companies like Teva Pharmaceuticals (TEVA), Pfizer (PFE), Johnson & Johnson (JNJ) and Allergan (AGN). Companies with big stakes in the pain-treatment game.
But the legal-pot business faces another formidable foe.